Michelle M Kittleson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9332293/publications.pdf

Version: 2024-02-01

279798 243625 2,229 96 23 44 citations h-index g-index papers 111 111 111 2749 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e7-e22.	1.6	338
2	Asymptomatic Antibody-mediated Rejection After Heart Transplantation Predicts Poor Outcomes. Journal of Heart and Lung Transplantation, 2009, 28, 417-422.	0.6	190
3	Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1320-1326.	0.6	145
4	Predicted heart mass is the optimal metric for size match in heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 156-165.	0.6	138
5	Kidney Function and Outcomes in Patients Hospitalized With HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 330-343.	2.8	90
6	Early Denervation and Later Reinnervation of the Heart Following Cardiac Transplantation: A Review. Journal of the American Heart Association, 2016, 5, .	3.7	83
7	Randomized Pilot Trial of Gene Expression Profiling Versus Heart Biopsy in the First Year After Heart Transplant. Circulation: Heart Failure, 2015, 8, 557-564.	3.9	74
8	Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. Journal of Heart and Lung Transplantation, 2017, 36, 787-796.	0.6	71
9	Intermediate outcomes with ex-vivo allograft perfusion for heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 258-263.	0.6	61
10	INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	59
11	Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Cardiology, 2020, 5, 1048.	6.1	58
12	COVID-19 vaccination in our transplant recipients: The time is now. Journal of Heart and Lung Transplantation, 2021, 40, 169-171.	0.6	52
13	Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry. Journal of Heart and Lung Transplantation, 2019, 38, 408-417.	0.6	47
14	Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. American Journal of Transplantation, 2021, 21, 2479-2488.	4.7	41
15	Antibody-mediated rejection. Current Opinion in Organ Transplantation, 2012, 17, 551-557.	1.6	38
16	INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. Journal of Heart and Lung Transplantation, 2020, 39, 16-26.	0.6	38
17	Remote monitoring in heart failure: current and emerging technologies in the context of the pandemic. Heart, 2021, 107, 366-372.	2.9	36
18	Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. JAMA Cardiology, 2018, 3, 1206.	6.1	35

#	Article	IF	Citations
19	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
20	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings, 2020, 52, 2711-2714.	0.6	33
21	Induction Therapy With Antithymocyte Globulin in Patients Undergoing Cardiac Transplantation Is Associated With Decreased Coronary Plaque Progression as Assessed by Intravascular Ultrasound. Circulation: Heart Failure, 2016, 9, e002252.	3.9	32
22	High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. Journal of Heart and Lung Transplantation, 2016, 35, 722-730.	0.6	28
23	The Invisible Hand â€" Medical Care during the Pandemic. New England Journal of Medicine, 2020, 382, 1586-1587.	27.0	27
24	A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal of Cardiac Failure, 2022, 28, 831-834.	1.7	24
25	Mechanical circulatory support for cardiac amyloidosis. Clinical Transplantation, 2019, 33, e13663.	1.6	22
26	Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation. Circulation: Heart Failure, 2020, 13, e006696.	3.9	22
27	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. JAMA Cardiology, 2021, 6, 267.	6.1	22
28	Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. Journal of Heart and Lung Transplantation, 2015, 34, 1630-1633.	0.6	21
29	Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care. Circulation: Heart Failure, 2021, 14, e008573.	3.9	21
30	Pregnancy after Heart Transplantation. Journal of Cardiac Failure, 2021, 27, 176-184.	1.7	19
31	Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant. Journal of Heart and Lung Transplantation, 2021, 40, 970-980.	0.6	18
32	Practice Patterns Surrounding Pregnancy After Heart Transplantation. Circulation: Heart Failure, 2020, 13, e006811.	3.9	17
33	Updates in Cardiac Amyloidosis Diagnosis and Treatment. Current Oncology Reports, 2021, 23, 47.	4.0	17
34	Intersection of Heart Failure and Pregnancy: Beyond Peripartum Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e008223.	3.9	16
35	Acceptable Post–Heart Transplant Outcomes Support Temporary MCS Prioritization in the New OPTN UNOS Heart Allocation Policy. Transplantation Proceedings, 2021, 53, 353-357.	0.6	13
36	Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. Transplantation Proceedings, 2021, 53, 329-334.	0.6	13

#	Article	IF	Citations
37	Impact of the United Network for organ sharing 2018 donor heart allocation system on transplant morbidity and mortality. Clinical Transplantation, 2021, 35, e14181.	1.6	13
38	Recent advances in heart transplantation. F1000Research, 2018, 7, 1008.	1.6	12
39	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. Journal of Cardiac Failure, 2022, 28, 1149-1157.	1.7	12
40	Heart Transplantation in Women. Heart Failure Clinics, 2019, 15, 127-135.	2.1	11
41	Does ex vivo perfusion lead to more or less intimal thickening in the firstâ€year post–heart transplantation?. Clinical Transplantation, 2019, 33, e13648.	1.6	10
42	Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients. Human Immunology, 2020, 81, 671-674.	2.4	10
43	Intermediateâ€term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clinical Transplantation, 2021, 35, e14308.	1.6	10
44	Innovations in Heart Transplantation: A Review. Journal of Cardiac Failure, 2022, 28, 467-476.	1.7	9
45	cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events. Frontiers in Physiology, 2020, 11, 503.	2.8	7
46	JC virusâ€associated nephropathy in a postâ€heart and â€kidney transplantation patient. Transplant Infectious Disease, 2020, 22, e13288.	1.7	7
47	The impact of depression on heart transplant outcomes: A retrospective singleâ€center cohort study. Clinical Transplantation, 2021, 35, e14204.	1.6	7
48	Solid Gold, or Liquid Gold?. Circulation, 2021, 143, 1198-1201.	1.6	7
49	The effects of donorâ€specific antibody characteristics on cardiac allograft vasculopathy. Clinical Transplantation, 2021, 35, e14483.	1.6	7
50	Symptomology following mRNA vaccination against SARS-CoV-2. Preventive Medicine, 2021, 153, 106860.	3.4	7
51	Defining Ambulatory Advanced Heart Failure: MedaMACS and Beyond. Current Heart Failure Reports, 2017, 14, 498-506.	3.3	6
52	Beyond the eyeball test: Impact and potential mechanisms of frailty in heart transplant candidates. Journal of Heart and Lung Transplantation, 2021, 40, 95-98.	0.6	6
53	Caregiver Healthâ€Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL. Journal of the American Heart Association, 2021, 10, e019901.	3.7	6
54	Donation after Circulatory Death: Extending the Boundaries of this New Frontier. Journal of Heart and Lung Transplantation, 2021, 40, 1419-1421.	0.6	6

#	Article	IF	CITATIONS
55	The Role of Echocardiography in the Management of Heart Transplant Recipients. Diagnostics, 2021, 11, 2338.	2.6	6
56	The Trials of Women in Cardiology. Journal of the American College of Cardiology, 2020, 76, 1931-1933.	2.8	5
57	Covid-19 in recipients of heart and lung transplantation: Learning from experience. Journal of Heart and Lung Transplantation, 2021, 40, 948-950.	0.6	5
58	Right Heart Catheterization in Patients with Advanced Heart Failure. Heart Failure Clinics, 2021, 17, 647-660.	2.1	5
59	Advanced heart failure: state of the art and future directions. Reviews in Cardiovascular Medicine, 2022, 23, 048.	1.4	5
60	A Good Physician — On Complacency and Communication. New England Journal of Medicine, 2019, 381, 1798-1799.	27.0	4
61	Clinical Utility of SPECT in the Heart Transplant Population. Transplantation, 2021, Publish Ahead of Print, .	1.0	4
62	The Role of Intravascular Ultrasound in Heart Transplant Recipients in the Modern Era. Journal of Cardiac Failure, 2021, 27, 473-476.	1.7	4
63	The Universal Definition of Heart Failure: Strengths and Opportunities. Journal of Cardiac Failure, 2021, 27, 622-624.	1.7	4
64	An early relook identifies high-risk trajectories in ambulatory advanced heart failure. Journal of Heart and Lung Transplantation, 2022, 41, 104-112.	0.6	4
65	Eculizumab for antibodyâ€mediated rejection in heart transplantation: A caseâ€control study. Clinical Transplantation, 2021, , e14454.	1.6	4
66	Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support. Journal of Heart and Lung Transplantation, 2022, 41, 365-372.	0.6	4
67	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. Journal of Cardiac Failure, 2022, 28, 554-563.	1.7	4
68	Pregnancy after heart transplantation: A need for updated guidelines. Journal of Heart and Lung Transplantation, 2020, 39, 1159.	0.6	3
69	Trust in the Time of COVID-19. American Journal of Medicine, 2020, 133, 1370-1371.	1.5	3
70	Heart transplant in Jehovah's Witness patients: A case-control study. Journal of Heart and Lung Transplantation, 2021, 40, 575-579.	0.6	3
71	Heart transplantation after total artificial heart bridging—Outcomes over 15 years. Clinical Transplantation, 2022, 36, .	1.6	3
72	The Impact of a High-risk Psychosocial Assessment on Outcomes After Durable Mechanical Circulatory Support. ASAIO Journal, 2021, 67, 436-442.	1.6	2

#	Article	IF	CITATIONS
73	Longâ€term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A singleâ€center experience. Clinical Transplantation, 2022, , e14591.	1.6	2
74	In-Hospital Outcomes in Pregnancy After Heart Transplantation. American Journal of Cardiology, 2022, 172, 68-72.	1.6	2
75	Transplanting COVID-19 positive donors: Expanding our experience to widen the donor pool. Journal of Heart and Lung Transplantation, 2022, 41, 1382-1384.	0.6	2
76	Nesiritide and Me. Circulation: Heart Failure, 2018, 11, e005440.	3.9	1
77	Mechanical Circulatory Support as a Bridge-to-Transplant Candidacy: When Does It Work?. ASAIO Journal, 2022, 68, 499-507.	1.6	1
78	A Blueprint for Productive Maintenance of Certification, But Is the American Board of Internal Medicine up to the Challenge?. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006696.	2.2	1
79	Biology or Disparity? Untangling Racial Differences in Val122Ile Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2022, 28, 960-962.	1.7	1
80	The Privilege of Grief. Annals of Internal Medicine, 2018, 169, 729.	3.9	0
81	Predictions are difficult, especially about the future. Journal of Heart and Lung Transplantation, 2018, 37, 824-825.	0.6	0
82	Mistakes. JAMA - Journal of the American Medical Association, 2019, 322, 984.	7.4	0
83	Predictions. JAMA Cardiology, 2019, 4, 1063.	6.1	0
84	142 Days. JAMA Cardiology, 2019, 4, 309.	6.1	0
85	Trading Lives. American Journal of Medicine, 2019, 132, 1486-1487.	1.5	0
86	My First Terrible Diagnosis. Academic Medicine, 2019, 94, 1488-1488.	1.6	0
87	Response by Alyesh et al to Letter Regarding Article, "A Blueprint for Productive Maintenance of Certification, but Is the American Board of Internal Medicine up to the Challenge?― Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007961.	2.2	0
88	Heart Transplantation for Adriamycin Cardiomyopathy. JACC: CardioOncology, 2021, 3, 302-304.	4.0	0
89	The challenge of heart transplantation in sensitized patientsâ€"carfilzomib and the importance of shared experience. Journal of Heart and Lung Transplantation, 2021, 40, 604-606.	0.6	0
90	Outcomes of cardiogenic shock with autoimmune rheumatological disorders. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0

#	Article	IF	CITATIONS
91	Advanced heart failure and heart transplantation in adult congenital heart disease in the current era. Clinical Transplantation, 2021, 35, e14451.	1.6	O
92	Heart transplantation in muscular dystrophy: Singleâ€eenter analysis. Clinical Transplantation, 2022, , e14645.	1.6	0
93	Cardiac microstructural alterations in immune-inflammatory myocardial disease: a retrospective case-control study. Cardiovascular Ultrasound, 2022, 20, 9.	1.6	O
94	The Two Pandemics. American Journal of Medicine, 2022, , .	1.5	0
95	When the Price Is Right: Beyond the Medical Risks and Benefits of Costly Therapies. Journal of the American Heart Association, 2022, 11 , .	3.7	O
96	Recurrent Myocarditis Treated with Intravenous Immune Globulin and Steroids. American Journal of Case Reports, 0, 23, .	0.8	0